Probiotic strategies for the treatment and prevention of bacterial vaginosis (Q37809873)

23 August 2017

Probiotic strategies for the treatment and prevention of bacterial vaginosis (English)

1 reference

23 August 2017

0 references

5

Gregor Reid

1 reference

23 August 2017

Roderick A MacPhee

1

1 reference

23 August 2017

Ruben Hummelen

series ordinal

2

1 reference

23 August 2017

Jordan E Bisanz

series ordinal

3

1 reference

23 August 2017

Wayne L Miller

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

2985-2995

1 reference

23 August 2017

18

1 reference

The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Deep sequencing of the vaginal microbiota of women with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Targeting the vaginal microbiota with probiotics as a means to counteract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Antimicrobial components of vaginal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Racial disparity in risk of preterm birth associated with lower genital tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Bacterial vaginosis, race, and sexually transmitted infections: does race modify the association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Molecular identification of bacteria associated with bacterial vaginosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Nucleic acid-based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Evidence of African-American women's frustrations with chronic recurrent bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Vulvovaginal symptoms in women with bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Evidence of a gene-environment interaction that predisposes to spontaneous preterm birth: a role for asymptomatic bacterial vaginosis and DNA variants in genes that control the inflammatory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Elafin (SKALP/Trappin-2/proteinase inhibitor-3) is produced by the cervix in pregnancy and cervicovaginal levels are diminished in bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Detection of a Lactobacillus substance that inhibits Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Control of the Microbial Flora of the Vagina by H202-Generating Lactobacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Utilization of the intestinal tract as a delivery system for urogenital probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Receptivity for probiotic products among premenopausal female students in an African university.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Colonization of the Rectum byLactobacillusSpecies and Decreased Risk of Bacterial Vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.512004

10.1517/14656566.2010.512004

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference